Risk factors

Aspire Biopharma Holdings (ASBP) risk factors

Item 1A of every Aspire Biopharma Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ASBP in Gloom →
Aspire Biopharma Holdings' chart, financials and news, free in your browser.Open ASBP in Gloom →
  • FY2025 10-K risk factors
    37 risks1 new1 dropped2 reworded

    Aspire added risks regarding vitamin and ED product development alongside caffeine manufacturing agreements. Melatonin development progressed with patent filings. High-dose aspirin clinical trials concluded in July 2025.

    Filed Mar 30, 2026
  • FY2024 10-K risk factors
    37 risks

    Aspire faces significant clinical and financial risks developing sublingual pharmaceuticals without prior profitable operating history.

    Filed Apr 07, 2025